Details of the Drug
General Information of Drug (ID: DMT0DW4)
| Drug Name |
Rotigitine
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Rotigotine hydrochloride; 125572-93-2; Rotigotine HCl; Rotigotine (Hydrochloride); UNII-6Q1W9573L2; (S)-6-(Propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol hydrochloride; 6Q1W9573L2; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol hydrochloride; [14C]-Rotigotine; N-0923 hydrochloride; N 0924 hydrochloride; Rotigotine(Hydrochloride); Neupro Hydrochloride Salt; C19H26ClNOS; AC1L46ZH; (S)-5,6,7,8-Tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol hydrochlor
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 |
Molecular Weight | 351.9 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||||||
| Rotatable Bond Count | 6 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Parkinson disease | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 8A00.0 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


